timothy sykes logo
MEDS Stock Soars As AI Oncology Bet Ignites Trading Frenzy Thumbnail
G Google News

MEDS Stock Soars As AI Oncology Bet Ignites Trading Frenzy

TIM SYKES•UPDATED SEP. 28, 2026, 9:19 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

DataMeds AI Inc. stocks have been trading up by 29.82 percent after groundbreaking clinical-trial AI platform results spurred investor optimism.

Key Takeaways For MEDS Traders

  • Helomics acquisition gives DataMeds AI a CLIA/CAP-certified cancer diagnostics lab, contracts, and $1.5M in cash in a $1.5M stock-and-note deal with no major assumed debt.
  • Following the Helomics news, MEDS ripped roughly 300% on huge trading volume, putting the ticker squarely on momentum screens.
  • Litigation tied to the 2023 Wellgistics agreement was settled, wiping about $19M in liabilities and retiring 364,099 shares for a $450,000 cash payment.
  • The “Health Lives Here” campaign and app with Tollo Health and the NFL Alumni Association leverages a 6,500+ pharmacy network, telehealth, AI, and blockchain to target underserved communities.
  • DataMEDS AI rolled out a new AI-focused website, is preparing a Health Lives Here app soft launch, and will showcase its platform at the 2026 National Telehealth and Virtual Care Summit.

Candlestick Chart

Live Update At 09:18:42 EDT: On Monday, September 28, 2026 DataMeds AI Inc. stock [NASDAQ: MEDS] is trending up by 29.82%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

MEDS is trading like a story stock, and the chart shows it. In early September, DataMeds AI sat under $1, closing near $0.87 on 2026/09/14. Then the Helomics deal hit. By 2026/09/16, MEDS exploded intraday from about $4 to a $12.31 high before closing at $6.07. That is classic parabolic action. Since then, the stock has pulled back sharply, with recent daily closes slipping from $4.27 on 2026/09/22 to $3.11 on 2026/09/25.

Under the hood, DataMEDS AI is still highly speculative. Revenue over the last period was about $23.3M, but margins are brutally negative, with EBITDA around -$16.4M and profit margins deep in the red. The balance sheet shows only about $2.46M in cash and heavy liabilities, with current ratio near 0.1, signaling tight liquidity. Return on assets is sharply negative, and book value per share is below zero.

More Breaking News

For traders, that mix—massive loss-making, weak balance sheet, and powerful news catalysts—often means elevated volatility, big intraday ranges, and the need for strict risk control on MEDS.

Why Traders Are Watching MEDS Now

DataMeds AI has turned itself into a momentum magnet. The Helomics acquisition is the core driver. For $1.5M in stock and notes, MEDS picked up an AI-driven cancer diagnostics and predictive oncology CRO lab, a CLIA/CAP-certified facility, equipment, and an existing contract research business—plus $1.5M in cash coming in the door. Crucially, the company did not take on third-party debt or legacy payables beyond normal operating costs. That is a rare structure for a tiny healthcare name.

Traders like this kind of asymmetric setup. MEDS is expanding beyond chronic conditions into oncology, a higher-value space, while management talks about broader cancer screening, molecular profiling, standard CLIA services, and even nutritional support for cancer patients. That is multiple potential revenue lines wrapped into one acquisition.

The market reaction shows how aggressive the re-rating was. After the Helomics deal closed, DataMEDS AI spiked more than 300% on extraordinary volume, with a separate headline citing a roughly 305% surge. Those are the types of moves day traders hunt, but they also invite fast reversals as late buyers get trapped.

At the same time, MEDS is cleaning up old baggage. The company settled litigation tied to its 2023 Wellgistics membership purchase, wiping about $19M in liabilities and retiring 364,099 shares for $450,000 in cash. For short-term trading, that reduces headline risk and simplifies the capital structure just as the AI-oncology story takes center stage.

Layer on the “Health Lives Here” campaign with Tollo Health and the NFL Alumni Association, a 6,500+ pharmacy network, telehealth, the EinsteinRx AI engine, and PharmacyChain blockchain smart contracts, and MEDS is clearly trying to rebrand as a full-stack health IT and services platform. Add an AI-focused website, a planned consumer app soft launch, and a slot at the 2026 National Telehealth and Virtual Care Summit—plus a pending multi-party transaction with DataVault AI—and you have a steady pipeline of potential catalysts that keep DataMeds AI on many watchlists.

Conclusion

For active traders, MEDS is the definition of a high-risk, high-reward news play. DataMeds AI has stitched together an aggressive narrative: AI cancer diagnostics with Helomics, a cleaner balance sheet after eliminating roughly $19M in liabilities, and a national “Health Lives Here” rollout that ties together pharmacies, telehealth, AI, and blockchain. Every one of those elements can move the tape, but none of them erase the reality of deep losses, negative equity, and tight liquidity.

The recent price history underlines that tension. MEDS went from sub-$1 to a double-digit intraday spike, then faded back into the $3–$4 range within days. That is textbook parabolic boom and unwind. Traders who chase without a plan are the ones who usually donate to the market here.

For those studying DataMEDS AI, the focus should be on timing catalysts, watching volume, and respecting key intraday levels rather than believing any single headline. As Tim Sykes likes to remind his community, “The market doesn’t care about your opinion, only your discipline—cut losses quickly and let the best setups come to you.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. MEDS offers plenty of action, but it demands that level of discipline. This coverage is for educational and research purposes only and should be used as one piece of a broader trading plan.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”